Table 1.
Clinical and biochemical data groups in type 2 diabetes treated with 1200 IU α-tocopherol/day or placebo for 4 weeks
| α-tocopherol Group (n = 10) | Placebo Group (n = 9) | |||
| Day 0 | Day 29 | Day 0 | Day 29 | |
| Age (Y) | 62.7 (1.81) | __ | 61.9 (1.92) | __ |
| Diabetes duration | 11.1 (2.52) | __ | 2.6 (0.4)a | __ |
| BMI | 29.9 (1.2) | __ | 29.4 (1.3) | __ |
| WHR | 0.92 (0.026) | __ | 0.94 (0.021) | __ |
| Fasting plasma glucose (mmol/L) | 10.7 (0.94) | 10.2 (0.86) | 7.6 (0.39)a | 7.7 (0.41)b |
| Fasting plasma insulin (mU/L) | 49.6 (6.67) | 56.2 (9.91) | 55.5 (7.81) | 54.5 (6.87) |
| Post-GTT plasma glucose (mmol/L) | 20.2 (1.25)c | 19.1 (1.26)c | 15.1 (0.94)c | 15.0 (1.32)c |
| Post-GTT plasma insulin (mU/L) | 135 (37.1)d | 124 (31.9)d | 218 (47.7)c | 261 (87.0)d |
| HbA1c (%) | 8.4 (0.6) | __ | 7.2 (0.3) | __ |
| Plasma α-tocopherol (μmol/L) | 28.9 (1.82) | 66.5 (7.26)e | 24.4 (1.71) | 25.0 (1.78) |
| 8-oxoquanine fluorescence (MFI) | 462 (28.0) | 456 (19.0) | 506 (27.1) | 495 (15.2) |
Data shown are means (SE)
a p < 0.01 placebo v α-tocopherol; b p < 0.05 placebo v α-tocopherol;
c p < 0.01 Fasting v post-GTT; d p < 0.05 Fasting v post-GTT
e p < 0.01 Day 0 v Day 29